OpGen Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
OpGen's earnings have been declining at an average annual rate of -12.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 5.6% per year.
Anahtar bilgiler
-12.8%
Kazanç büyüme oranı
57.0%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | -5.6% |
Özkaynak getirisi | n/a |
Net Marj | -1,139.7% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
OpGen to raise $3.38M in direct stock offering
Sep 30OpGen's subsidiary signs R&D agreement with FIND
Sep 20Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement
Aug 31OpGen launches sequencing services for infectious diseases in US
Aug 25OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line
Aug 11OpGen reports preliminary revenue estimate for Q2 2022
Jul 08OpGen gains on insider buying
Jun 15OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates
Jun 07OpGen reports prelim Q4 & FY20 revenue
Jan 13OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia
Jan 05OpGen launches $10M private placement
Nov 24OpGen EPS misses by $0.04, beats on revenue
Nov 11OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform
Oct 28Gelir ve Gider Dağılımı
OpGen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 2 | -22 | 7 | 0 |
31 Mar 24 | 3 | -27 | 9 | 0 |
31 Dec 23 | 3 | -33 | 11 | 0 |
30 Sep 23 | 3 | -26 | 13 | 0 |
30 Jun 23 | 3 | -36 | 13 | 0 |
31 Mar 23 | 3 | -36 | 13 | 0 |
31 Dec 22 | 3 | -37 | 13 | 0 |
30 Sep 22 | 3 | -41 | 14 | 0 |
30 Jun 22 | 4 | -33 | 14 | 0 |
31 Mar 22 | 4 | -34 | 14 | 0 |
31 Dec 21 | 4 | -42 | 14 | 0 |
30 Sep 21 | 4 | -35 | 13 | 0 |
30 Jun 21 | 4 | -37 | 13 | 0 |
31 Mar 21 | 4 | -37 | 13 | 0 |
31 Dec 20 | 4 | -26 | 12 | 0 |
30 Sep 20 | 4 | -22 | 10 | 0 |
30 Jun 20 | 3 | -17 | 9 | 0 |
31 Mar 20 | 3 | -13 | 8 | 0 |
31 Dec 19 | 3 | -12 | 8 | 0 |
30 Sep 19 | 3 | -14 | 8 | 0 |
30 Jun 19 | 3 | -13 | 8 | 0 |
31 Mar 19 | 3 | -14 | 9 | 0 |
31 Dec 18 | 3 | -13 | 9 | 0 |
30 Sep 18 | 3 | -13 | 8 | 0 |
30 Jun 18 | 3 | -13 | 8 | 0 |
31 Mar 18 | 3 | -13 | 9 | 0 |
31 Dec 17 | 3 | -15 | 9 | 0 |
30 Sep 17 | 3 | -17 | 11 | 0 |
30 Jun 17 | 3 | -19 | 12 | 0 |
31 Mar 17 | 4 | -20 | 12 | 0 |
31 Dec 16 | 4 | -19 | 12 | 0 |
30 Sep 16 | 4 | -19 | 13 | 0 |
30 Jun 16 | 5 | -19 | 12 | 0 |
31 Mar 16 | 4 | -19 | 11 | 0 |
31 Dec 15 | 3 | -18 | 10 | 0 |
30 Sep 15 | 3 | -14 | 8 | -3 |
30 Jun 15 | 3 | -12 | 6 | 0 |
31 Mar 15 | 4 | -8 | 5 | 0 |
31 Dec 14 | 4 | -6 | 4 | 0 |
30 Sep 14 | 4 | -9 | 4 | 3 |
31 Dec 13 | 2 | -16 | 6 | 0 |
Kaliteli Kazançlar: OPGN is currently unprofitable.
Büyüyen Kar Marjı: OPGN is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: OPGN is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.
Büyüme Hızlandırma: Unable to compare OPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: OPGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: OPGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.